Neal Shore, MD, is the Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 400 clinical trials, focusing on GU Oncology indications. He is the Chief Medical Officer, Surgery/Urology, for GenesisCare,US. Dr. Shore serves on the SITC Guidelines Committee for Bladder Cancer and the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee. Dr. Shore is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and serves as Editor for Everyday Urology-Oncology. Also, he’s a Fellow of the American College of Surgeons.

John Gore, MD, MS, FACS is a urologic oncologist and health services researcher. Dr. Gore is a Professor in Urology, Adjunct Professor in Surgery at the University of Washington, and Affiliate Investigator at the Fred Hutchinson Cancer Research Center. He is the Program Director of the UW SUO Fellowship in Urologic Oncology and has served as the primary mentor on 13 extramural mentored research awards including from the Urology Care Foundation, DOD, ASCO Conquer Cancer Foundation, Bladder Cancer Advocacy Network, and NIH. Dr. Gore is pursuing a translational health services and patient-centered outcomes research program toward improving access to care, quality of life, and quality of care for urologic cancers. He has active funding from PCORI, NIH, American Cancer Society, and DOD.

Joshua Meeks, MD, PhD, is an Associate Professor of Urology, Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, as well as Section Chief of Robotic Surgery at the Jesse Brown VA Medical Center. He is a urologic surgeon with expertise in the diagnosis, treatment and management of bladder cancer. Dr. Meek’s research interests focus on the epigenetics and genetic mutations associated with cancer biology, specifically on how chromatin remodeling genes play a role in bladder cancer. In 2019, Dr. Meeks was the National Surgery Office VHA Chair of the Urology Surgical Advisory Board and on the Society of Urologic Oncology Fall Meeting Bladder Planning Committee. Currently, he serves on the Editorial Board of the Journal Surgical Oncology.

Matthew Galsky, MD, is the director of genitourinary medical oncology at the Mount Sinai School of Medicine Tisch Cancer Institute in New York. Dr Galsky specializes in caring for patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the clinical development of novel therapies for genitourinary cancers, with a particular emphasis on bladder cancer, and he regularly speaks nationally and internationally on the topic. His research has been published in numerous journals, including the Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet Oncology and Lancet, and has been funded by organizations that include the National Institutes of Health/National Cancer Institute and the Department of Defense.

Arjun V. Balar, MD, is the Director of the Genitoruinary Medical Oncology Program at the Perlmutter Cancer Center at New York University (NYU) Langone Health and an Assistant Professor at NYU School of Medicine. Dr. Balar’s research focuses on bladder cancer and immunotherapy as well as molecularly targeted therapy. His main research focal point is on novel immunotherapies and combinations with the goal of identifying better tolerated and more effective therapies in advanced urothelial cancer; as such, clinical trial findings from Dr. Balar led to accelerated FDA approval of two drugs for advanced bladder cancer. Furthermore, Dr. Balar works closely with surgeons and radiation oncologists to enhance multidisciplinary care models and with basic scientists to foster traditional research.